Published in Eur Urol on December 26, 2006
Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma | NCT03390595
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (2008) 2.53
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol (2010) 1.26
Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol (2011) 1.11
First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol (2011) 0.96
Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. Eur Urol (2011) 0.93
Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford) (2010) 0.91
Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther (2011) 0.90
Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol (2012) 0.90
Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics. Transl Oncol (2015) 0.89
Perioperative chemotherapy for upper tract urothelial cancer. Nat Rev Urol (2012) 0.87
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol (2012) 0.87
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist (2016) 0.83
The role of chemotherapy in upper tract urothelial carcinoma. Adv Urol (2009) 0.83
Chemotherapy for bladder cancer in patients with impaired renal function. Nat Rev Urol (2011) 0.83
Systemic therapy for bladder cancer - a medical oncologist's perspective. J Solid Tumors (2014) 0.82
A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium. BMC Cancer (2007) 0.81
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol (2016) 0.81
The Prognostic Impact of Histopathological Variants in Patients with Advanced Urothelial Carcinoma. PLoS One (2015) 0.80
Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling. Exp Ther Med (2010) 0.80
Update on chemotherapy in the treatment of urothelial carcinoma. ScientificWorldJournal (2011) 0.80
Urothelial carcinoma management in elderly or unfit patients. EJC Suppl (2016) 0.78
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. Cancer (2015) 0.78
Chemotherapy in advanced bladder cancer: current status and future. J Hematol Oncol (2011) 0.78
Difference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitant. Mol Clin Oncol (2012) 0.77
Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin? Eur Urol (2007) 0.77
The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. Int J Clin Oncol (2016) 0.76
Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin - preliminary results. Cent European J Urol (2012) 0.76
Metastatic bladder cancer: a review of current management. ISRN Urol (2011) 0.76
Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma. Int J Clin Oncol (2016) 0.76
Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center. Mol Clin Oncol (2015) 0.75
Gemcitabine and Carboplatin (renally dosed) regimen for bladder cancer. Hosp Pharm (2015) 0.75
Systemic therapy in bladder cancer. Indian J Urol (2017) 0.75
Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy. Ther Adv Med Oncol (2010) 0.75
Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. Mol Clin Oncol (2016) 0.75
Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients. J Negat Results Biomed (2015) 0.75
Novel agents for advanced bladder cancer. Ther Adv Med Oncol (2009) 0.75
Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer. Oncotarget (2017) 0.75
The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers. Int J Clin Oncol (2012) 0.75
Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency. Int J Clin Oncol (2012) 0.75
Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response. World J Urol (2011) 0.75
Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer. Int J Clin Oncol (2015) 0.75
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 11.04
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol (2010) 7.70
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol (2010) 5.10
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys (2006) 4.26
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol (2005) 3.93
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst (2002) 3.54
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol (2005) 3.19
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87
A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol (2006) 2.80
Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol (2012) 2.77
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol (2012) 2.76
The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer (2005) 2.69
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol (2010) 2.69
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol (2008) 2.57
Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol (2012) 2.46
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol (2008) 2.44
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst (2007) 2.42
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol (2008) 2.40
Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA (2005) 2.31
Managing chronic pain: results from an open-label study using MC5-A Calmare® device. Support Care Cancer (2011) 2.29
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol (2007) 2.19
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 2.17
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol (2012) 2.15
Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol (2011) 2.10
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol (2005) 2.10
Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A (2010) 2.05
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res (2013) 2.03
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A (2010) 1.99
Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics (2005) 1.99
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol (2012) 1.97
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol (2004) 1.95
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer (2009) 1.94
Concern WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.84
miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol (2013) 1.79
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med (2014) 1.79
Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle (2010) 1.73
2005 update on pathology of prostate biopsies with cancer. Eur Urol (2006) 1.66
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol (2008) 1.65
Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell (2013) 1.62
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol (2008) 1.61
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res (2003) 1.60
Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy (2011) 1.54
Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica (2006) 1.53
Prospective, multicenter, randomized trial of a new organizational modality for providing information and support to cancer patients. J Clin Oncol (2009) 1.52
18F-FDG PET/CT impact on testicular tumours clinical management. Eur J Nucl Med Mol Imaging (2013) 1.49
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol (2009) 1.48
Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2. Cancer Biol Ther (2006) 1.43
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs (2009) 1.42
Gastric cancer mortality in the spouses of patients who died from gastric cancer. Int J Epidemiol (2002) 1.41
Skull Base Plasmacytoma in a Patient with Light Chain Myeloma. Skull Base (2003) 1.40
Salvage treatment of relapsed or refractory germ-cell tumours. Lancet Oncol (2013) 1.39
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist (2013) 1.35
Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer (2010) 1.33
Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol (2006) 1.33
p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol (2006) 1.32
Targeted therapies: how personal should we go? Nat Rev Clin Oncol (2011) 1.31
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol (2005) 1.31
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer (2009) 1.31
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat (2006) 1.29
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol (2009) 1.27
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer (2013) 1.26
Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett (2013) 1.24
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int (2011) 1.24
Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol (2009) 1.19
Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC. Int J Mol Sci (2013) 1.15
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol (2006) 1.14
Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol (2005) 1.13
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med (2015) 1.12
Handling and pathology reporting of prostate biopsies. Eur Urol (2004) 1.11
c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat (2004) 1.11
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res (2011) 1.10
Regorafenib for metastatic colorectal cancer. Lancet (2013) 1.09
Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J (2004) 1.08